Leronlimab for Alzheimer's Disease

(SALIENT-AD Trial)

This trial tests the safety of leronlimab, a drug used in other conditions like HIV, to determine its potential benefits for people with Alzheimer's disease or mild cognitive impairment from Alzheimer's. Researchers aim to assess whether leronlimab is safe and can reduce brain inflammation in these individuals. Those who have had Alzheimer's or mild cognitive impairment for a while and are on stable medication for at least 12 weeks might be suitable candidates for this study. Participants will take the drug once a week for 12 weeks and undergo various tests, including brain scans and cognitive assessments. As a Phase 2 trial, this research focuses on evaluating leronlimab's effectiveness in an initial, smaller group, offering a chance to contribute to important findings.

You may not need to stop your current medications, but you must be on a stable dose of any Alzheimer's medications, brain-targeting drugs, or supplements for at least 12 weeks before starting the trial. If you're on other allowed medications, they should be stable for at least 4 weeks unless the investigator decides otherwise.

Research has shown that leronlimab is considered safe for treating other diseases, such as HIV and certain types of breast cancer. Although it has been tested in people before, it has not been specifically tested for Alzheimer's disease. While safety data for Alzheimer's patients is not yet available, its use in other conditions offers some reassurance. As a Phase 2 trial, the drug has demonstrated some safety in earlier studies, but researchers are still testing to confirm its safety and effects in this new patient group. Participants must report any side effects during the trial, and researchers will monitor for any new issues.¹²³⁴⁵

Unlike the standard treatments for Alzheimer’s disease, which often focus on managing symptoms with medications like cholinesterase inhibitors or memantine, leronlimab acts on a unique mechanism. Leronlimab is a monoclonal antibody that targets the CCR5 receptor, which is believed to play a role in neuroinflammation and neuronal damage in Alzheimer’s. Researchers are excited about leronlimab because it offers a novel approach by potentially reducing inflammation in the brain, which could slow disease progression and improve cognitive function. This distinct mechanism of action sets it apart from existing therapies and holds promise for a more effective treatment strategy.

Research has shown that leronlimab, a drug also used for conditions like HIV, is under study for Alzheimer's disease (AD) in this trial. Although human data specifically for Alzheimer's is not yet available, leronlimab targets a protein called CCR5, which helps reduce inflammation. Since inflammation plays a key role in Alzheimer's, scientists believe leronlimab might help by lowering brain inflammation. While leronlimab is considered safe for other diseases, its exact effects on Alzheimer's patients remain under investigation. Early results appear promising, but further research is needed to confirm if it can slow memory and thinking problems.¹⁶⁷⁸⁹